0.00%
-16.37%
-10.64%
-10.64%
-36.39%
-62.77%
-89.03%
AI Spotlight on GLPG
Company Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need.Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis.The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.
In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis.The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG.Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Market Data
| Last Price | 22.18 |
| Change Percentage | 0.00% |
| Open | 22.26 |
| Previous Close | 22.18 |
| Market Cap ( Millions) | 1462 |
| Volume | 26954 |
| Year High | 37.17 |
| Year Low | 22 |
| M A 50 | 25.25 |
| M A 200 | 25.35 |
Financial Ratios
| FCF Yield | -27.53% |
| Dividend Yield | 0.00% |
| ROE | 7.20% |
| Debt / Equity | 0.40% |
| Net Debt / EBIDTA | 32.44% |
| Price To Book | 0.51 |
| Price Earnings Ratio | 7.08 |
| Price To FCF | -3.63 |
| Price To sales | -162.94 |
| EV / EBITDA | -10.44 |
News
- Jan -08 - Galapagos Plans to Split Into Two Entities, Revise Agreement With Gilead Sciences, Reduce Workforce by 40%
- Jan -08 - Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities
- Jan -07 - Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Dec -13 - Galapagos NV (AMS:GLPG) stock most popular amongst retail investors who own 56%, while public companies hold 25%
- Dec -11 - ASH 2024: Galapagos presents positive results for a seven-day ‘vein-to-vein’ CAR T-cell therapy
- Dec -07 - Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
- Nov -05 - Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024
- Nov -02 - Galapagos Third Quarter 2024 Earnings: €0.74 loss per share (vs €0.39 profit in 3Q 2023)
- Nov -01 - Galapagos NV (GLPG) Q3 2024 Earnings Call Highlights: Strong Cash Position and R&D Progress ...
- Oct -30 - Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update
- Oct -07 - Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth
- Sep -30 - Galapagos receives transparency notification from EcoR1 Capital
- Sep -16 - Galapagos receives transparency notification from EcoR1 Capital
- Sep -03 - Galapagos receives transparency notification from FMR LLC
- Sep -01 - Even after rising 13% this past week, Galapagos (AMS:GLPG) shareholders are still down 82% over the past five years
- Aug -28 - Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
- Aug -23 - Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study
- Aug -23 - Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma
- Aug -20 - Galapagos receives transparency notification from FMR LLC
- Aug -12 - ADAP: 2Q24 Earnings Review: Tecelra FDA Approval + Capital Reload
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Medicines
Expected Growth : 9.27 %
What the company do ?
Galapagos NV is a Belgian-Dutch biotech company that develops and commercializes innovative medicines for unmet medical needs, focusing on inflammation, fibrosis, and other diseases.
Why we expect these perspectives ?
Galapagos NV's 9.27% growth is driven by increasing demand for its innovative pipeline of orphan diseases treatments, strong partnerships with pharma giants, and expansion into new markets. Additionally, the company's focus on research and development, coupled with a strong cash position, enables it to invest in new technologies and opportunities, further fueling growth.
Galapagos Nv Products
| Product Range | What is it ? |
|---|---|
| COMPOUND LIBRARIES | Galapagos NV offers a comprehensive collection of compound libraries, including focused libraries, diversity libraries, and targeted libraries, to support drug discovery and development. |
| ADME-Tox SERVICES | Galapagos NV provides ADME-Tox services, including in vitro and in vivo studies, to assess the absorption, distribution, metabolism, excretion, and toxicity of compounds. |
| CELL-BASED ASSAYS | Galapagos NV offers cell-based assays, including reporter gene assays, functional assays, and phenotypic assays, to study cellular responses and identify potential drug targets. |
| IN VITRO PHARMACOLOGY SERVICES | Galapagos NV provides in vitro pharmacology services, including receptor binding assays, enzyme assays, and cell-based assays, to study the pharmacological activity of compounds. |
| IN VIVO PHARMACOLOGY SERVICES | Galapagos NV offers in vivo pharmacology services, including efficacy and safety studies, to evaluate the pharmacological activity of compounds in animal models. |
Galapagos NV's Porter Forces
Threat Of Substitutes
The threat of substitutes for Galapagos NV is moderate due to the presence of alternative technologies and products in the market.
Bargaining Power Of Customers
The bargaining power of customers for Galapagos NV is low due to the company's strong brand reputation and customer loyalty.
Bargaining Power Of Suppliers
The bargaining power of suppliers for Galapagos NV is moderate due to the presence of multiple suppliers in the market.
Threat Of New Entrants
The threat of new entrants for Galapagos NV is high due to the attractiveness of the market and the ease of entry for new competitors.
Intensity Of Rivalry
The intensity of rivalry for Galapagos NV is high due to the presence of several established competitors in the market.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 0.34% |
| Debt Cost | 3.95% |
| Equity Weight | 99.66% |
| Equity Cost | 4.14% |
| WACC | 4.14% |
| Leverage | 0.34% |
Galapagos NV : Quality Control
Galapagos NV passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CGEN | Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of … |
| HYL.BR | Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health, oncology, women's health, and other major therapeutic areas. The company … |
| MDWD | MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a … |
| BAVA.CO | Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under … |
| BSLN.SW | Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Galapagos
A-Score
1-Year Total Return ->
🥈
Bavarian Nordic
A-Score
1-Year Total Return ->
🥉
MediWound
A-Score
1-Year Total Return ->
4
Basilea Pharmaceutica
A-Score
1-Year Total Return ->
5
Compugen
A-Score
1-Year Total Return ->
6
